Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
103 results about "Modafinil" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Modafinil reduces extreme sleepiness due to narcolepsy and other sleep disorders, such as periods of stopped breathing during sleep (obstructive sleep apnea). It is also used to help you stay awake during work hours if you have a work schedule that keeps you from having a normal sleep routine (shift work sleep disorder). This medication does not cure these sleep disorders and may not get rid of all your sleepiness.
Reversal of General Anesthesia by Administration of Methylphenidate, Amphetamine, Modafinil, Amantadine, and/or Caffeine
ActiveUS20150196249A1High speedReduces and eliminates effectElectroencephalographyPharmaceutical delivery mechanismUnconsciousnessWhole body
Owner:THE GENERAL HOSPITAL CORP
Acetamide derivative having defined particle size
InactiveUSRE37516E1Reduce and eliminate symptomIncrease alertnessPowder deliveryBiocideMedicineSafety profile
Pharmaceutical compositions comprising modafinil in the form of particles of defined size. The particle size of modafinil can have a significant effect on the potency and safety profile of the drug.
Owner:CEPHALON INC
Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
A pharmaceutical composition comprising a co-crystal of an API and a co-crystal former; wherein the API has at least one functional group selected from ether, thioether, alcohol, thiol, aldehyde, ketone, thioketone, nitrate ester, phosphate ester, thiophosphate ester, ester, thioester, sulfate ester, carboxylic acid, phosphinic acid, phosphonic acid, sulfonic acid, amide, primary amine, secondary amine, ammonia, tertiary amine, imine, thiocyanate, cyanamide, oxime, nitrile diazo, organohalide, nitro, S-heterocyclic ring, thiophene, N-heterocyclic ring, pyrrole, 0-heterocyclic ring, furan, epoxide, peroxide, hydroxamic acid, imidazole, pyridine and the co-crystal former has at least one functional group selected from amine, amide, pyridine, imidazole, indole, pyrrolidine, carbonyl, carboxyl, hydroxyl, phenol, sulfone, sulfonyl, mercapto and methyl thio, such that the API and co-crystal former are capable of co-crystallizing from a solution phase under crystallization conditions.
Owner:UNIV OF SOUTH FLORIDA +3
Method for treating sleep-related breathing disorders
InactiveUS20060039866A1Excellent toneSuppressing REM sleepBiocideAerosol deliveryHypopneaPositive airway pressure
Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include mirtazapine in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.
Owner:CYPRESS BIOSCI
Pharmaceutical Compositions and Related Methods of Treatment
InactiveUS20080021074A1Decrease and prevent sleepinessDecrease and prevent and lethargyBiocideNervous disorderAdrenergic receptor agonistsClumsiness
Pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed. Pharmaceutical compositions comprising tizanidine and modafinil are disclosed. Methods for reducing somnolence, sleepiness, lethargy, dizziness, drowsiness, somnolence, tiredness, lightheadedness, increased weakness, confusion, unsteadiness, clumsiness, or a combination of the symptoms thereof in a human patient; treating pain; and attenuating muscle spasticity, using pharmaceutical compositions comprising at least one alpha2-adrenergic agonist or baclofen and at least one alpha1-adrenergic agonist are disclosed.
Owner:QUESTCOR PHARMA
Method for treating sleep-related breathing disorders with setiptiline
InactiveUS20060039867A1Excellent toneSuppressing REM sleepBiocideAerosol deliveryHypopneaPositive airway pressure
Compositions and methods for the treatment of sleep related breathing disorders are provided. Compositions include setiptiline in combination with other active pharmaceutical ingredients, such as zonisamide, topiramate or modafinil. The treated sleep related breathing disorders include sleep apnea and sleep hypopnea. In some embodiments, the pharmaceutical compounds are used as adjuvant therapy with positive airway pressure (PAP) therapy, thereby lowering the pressure required to maintain airway patency during PAP therapy.
Owner:CYPRESS BIOSCI
Modafinil compositions
InactiveUS20070021510A1Improve solubilityHigh dissolution rateBiocideOrganic active ingredientsSolubilityMedicine
Co-crystals and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and several important physical properties are modulated. The solubility, dissolution, bioavailability, dose response, and stability of modafinil can be modulated to improve efficacy in pharmaceutical compositions.
Owner:CEPHALON INC
Oxidation method for preparing highly pure modafinil, crystalline forms of modafinil, and methods of preparing the crystalline forms
The present invention provides an improved process for preparing modafinil, whereby it may be isolated in high purity by a single crystallization. The process produces modafinil free of sulphone products of over-oxidation and other byproducts. The invention further provides new crystalline Forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil Forms II-IV and VI.
Owner:TEVA PHARM USA INC
Modafinil oral lyophilizate
The invention concerns an oral lyophilizate comprising modafinil particles having a median diameter of about 10 to about 1000 μm in association with an appropriate amount of at least one excipient selected from the group consisting of fatty acid esters of glycerol, cyclic oligosaccharides, sweeteners or mixtures thereof.
Owner:CEPHALON FRANCE
Reversal of general anesthesia by administration of methylphenidate, amphetamine, modafinil, amantadine, and/or caffeine
InactiveUS20130310422A1High speedReduces and eliminates effectBiocidePharmaceutical delivery mechanismUnconsciousnessWhole body
The present invention generally relates to compositions comprising anesthesia-reversing agents which facilitate or increase the time of awakening or reverse the effects of general anesthesia-induced unconsciousness. In some embodiments, the anesthesia reversing agent can be selected from any or a combination of methylphenidate (MPH), amphetamine, modafinil, amantadine, caffeine, or analogues or derivatives thereof. In some embodiments, compositions comprising at least one or more anesthesia-reversing agents can be used to facilitate awakening from anesthesia without or decreasing occurrence of delirium, and can be used in methods to treat or prevent the symptoms associated with emergence delirium, as well as treat a subject oversedated with general an esthesia. The invention also relates to methods for administering these compositions comprising anesthesia-reversing agents to subjects and for use.
Owner:THE GENERAL HOSPITAL CORP
Rapid Onset and Short Term Modafinil Compositions and Methods of Use Thereof
InactiveUS20090123545A1Good conditionRapid onsetOrganic active ingredientsBiocideEnantiomerIntensive care medicine
Compositions are described that comprise a modafÊnil component that is a combination of the d- and l-enantiomers of modafinil and wherein the modafÊnil component is greater than 50% by weight d-modafÊnil for use in promoting or enhancing the state of wakefulness, alertness, and / or central nervous system stimulation in an individual.
Owner:NEUROHEALING PHARMA INC
Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
InactiveUS7317126B2High yieldOrganic compound preparationOrganic chemistry methodsOrganic solventEnantiomer
The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of:a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionallyb) isolating the obtained sulphoxide of formula (I);wherein n, Y, R1, R1a, R2 and R2a are as defined herein.
Owner:TEVA SANTE
Microbial sulfoxidation and amidation of benzhdrylsulfanyl carboxylic acids and uses thereof
The present invention provides novel methods for the synthesis of racemic and enantiomers of modafinil via microbial oxidation-amidation transformation. The methods include the successive oxidation-amidation of benzhydrylsulfanyl carboxylic acid to produce racemic and enantiomers of modafinil using at least one microorganism of yeast, bacteria, or fungus. Also disclosed are pharmaceutical compositions of racemic and enantiomers of modafinil along with their use in the treatment of diseases, including attention deficit hyperactivity disorder and drug addiction.
Owner:UNIV OF IOWA RES FOUND
Methods for the separation of enantiomeric sulfinylacetamides
InactiveUS20060086667A1High enantiomeric purityHigh yieldIon-exchange process apparatusIon-exchanger regenerationMedicinal chemistryModafinil
The present invention is directed to a process for the isolation of the enantiomeric forms of modafinil with high enantiomeric purity and high overall yields by means of a continuous chromatographic process.
Owner:CEPHALON INC
Combination dosage form of low-dose modafinil and low-dose sildenafil
InactiveUS20110033506A1Reducing and eliminating headacheAvoiding problematic and even dangerous side effectBiocideOrganic active ingredientsTime controlDelivery system
Modified release formulations comprising at least one of modafinil and sildenafil, and combinations thereof, and a time-controlled delivery system coating.
Owner:PENHASI ADEL +4
Modafinil compositions
Polymorphs and solvates of racemic, enantiomerically pure, and enantiomerically mixed modafinil are formed and discussed. In addition, said forms are described as useful for the treatment of many conditions including, but not limited to, narcolepsy.
Owner:CEPHALON INC
Nanoparticulate formulations of modafinil
InactiveUS20080317843A1Minimize changesQuick releaseBiocideOrganic active ingredientsSubstance abuserEnantiomer
The present invention is directed to compositions comprising a nanoparticulate modafinil compositions, or a salt(s), or an enantiomer(s), or a prodrug(s), or a polymorph(s) or derivative thereof, having improved bioavailability. The nanoparticulate modafinil composition formulation particles of the composition have an effective average particle size of less than about 2000 nm and are useful in the treatment of dyssomnias, including but not limited to, narcolepsy, chronic fatigue, eating disorders, compulsive behaviors, ADHD, addictions, substance abuse, sleepiness, nervous system diseases, conditions, syndromes, and symptoms and related diseases, conditions, and symptoms.
Owner:ELAN PHRMA INT LTD
Modafinil compound and cyclodextrin mixtures
Mixtures of a modafinil compound with a cyclodextrin, methods for their use, and compositions thereof are disclosed, along with complexes comprising a modafinil compound and a cyclodextrin which are taste-masked and suitable for oral consumption in an aqueous solution.
Owner:CEPHALON INC
Highly pure modafinil
The present invention provides an improved process for preparing modafinil, whereby it may be isolated in high purity by a single crystallization. The process produces modafinil free of sulphone products of over-oxidation and other byproducts. The invention further provides new crystalline Forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil Forms II-IV and VI.
Owner:TEVA PHARMA IND LTD
Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
InactiveUS7368591B2High enantioselectivityHigh yieldBiocideOrganic compound preparationOrganic solventEnantiomer
The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of:a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionallyb) isolating the obtained sulphoxide of formula (I).wherein n, Y, R1, R1a, R2 and R2a are as defined in claim 1.
Owner:TEVA SANTE
Treatment of obstructive sleep apnea syndrome with a combination of a carbonic anhydrase inhibitor and an additional active agent
InactiveUS20110224196A1Amelioration of the extent of each apneaAlleviate excessive daytime sleepinessBiocideNervous disorderZaleplonActive agent
This invention relates generally to methods and pharmaceutical formulations useful in treating patients suffering from obstructive sleep apnea syndrome (OSAS). Treatment of OSAS is effected by administering a carbonic anhydrase inhibitor to the patient in combination with at least one additional active agent. Examples of additional active agents include modafinil, eszopiclone, zolpidem, zaleplon, and phentermine.
Owner:VIVUS
Microbial sulfoxidation and amidation of benzhdrylsulfanyl carboxylic acids and uses thereof
The present invention provides novel methods for the synthesis of racemic and enantiomers of modafinil via microbial oxidation-amidation transformation. The methods include the successive oxidation-amidation of benzhydrylsulfanyl carboxylic acid to produce racemic and enantiomers of modafinil using at least one microorganism of yeast, bacteria, or fungus. Also disclosed are pharmaceutical compositions of racemic and enantiomers of modafinil along with their use in the treatment of diseases, including attention deficit hyperactivity disorder and drug addiction.
Owner:UNIV OF IOWA RES FOUND
Crystalline forms of modafinil
InactiveUS20050034652A1High purityOrganic active ingredientsPolycrystalline material growthOver oxidationX-ray
The present invention provides an improved process for preparing modafinil, whereby it may be isolated in high purity by a single crystallization. The process produces modafinil free of sulphone products of over-oxidation and other byproducts. The invention further provides new crystalline Forms II-VI of modafinil and processes for preparing them. Each of the new forms is differentiated by a unique powder X-ray diffraction pattern. The invention further provides pharmaceutical compositions containing novel modafinil Forms II-IV and VI.
Owner:TEVA PHARMA IND LTD
Modafinil compound and cyclodextrin mixtures
Mixtures of a modafinil compound with a cyclodextrin, methods for their use, and compositions thereof are disclosed, along with complexes comprising a modafinil compound and a cyclodextrin which are taste-masked and suitable for oral consumption in an aqueous solution.
Owner:CEPHALON INC
Process for enantioselective synthesis of single enantiomers of modafinil by asymmetric oxidation
InactiveUS20050080256A1High enantioselectivityHigh yieldOrganic compound preparationOptically-active compound separationOrganic solventEnantioselective synthesis
The invention relates to a method for preparing a sulphoxide compound of formula (I) either as a single enantiomer or in an enantiomerically enriched form, comprising the steps of: a) contacting a pro-chiral sulphide of formula (II) with a metal chiral complex, a base and an oxidizing agent in an organic solvent; and optionally b) isolating the obtained sulphoxide of formula (I); wherein n, Y, R1, R1a, R2 and R2a are as defined herein.
Owner:TEVA SANTE
Composition of the treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or derivatives thereof
ActiveUS9259412B2Prevention or treatmentInhibition of activationOrganic chemistryFood ingredient functionsDiseaseVascular disease
The present invention relates to modafinil or derivatives thereof as a medicine for the treatment of vascular diseases or KCa3.1 channel (Ca activated K channel) mediated diseases and a novel use of the same. More specifically, the present invention relates to a pharmaceutical composition for the prevention or treatment of vascular diseases or KCa3.1 channel-mediated diseases comprising modafinil or a derivative of modafinil, or pharmaceutically acceptable salts thereof which relax blood vessels and inhibit KCa3.1 channel currents by increasing intracellular cAMP, a method for treating vascular diseases or KCa3.1 channel-mediated diseases using the composition and a health functional food composition for the prevention or improvement of vascular diseases or the KCa3.1 channel-mediated diseases comprising modafinil or a modafinil derivative compound, or sitologically acceptable salts thereof.
Owner:CELLION BIOMED INC
Crystalline forms of modafinil
Owner:TEVA PHARMA IND LTD
New synthesizing process for modafinil
InactiveCN1986527ALow costHigh yieldOrganic chemistryOrganic compound preparationAcetic acidAcetyl chloride
The present invention discloses new process of synthesizing Modafinil, or 2-(diphenylmethyl sulfinyl) acetamide. The process includes the reaction of diphenyl methane as main material and bromine to obtain the intermediate diphenyl bromomethane, further condensation with mercapto acetic acid to obtain the intermediate diphenyl methylthio acetic acid, acyl chlorination to obtain the intermediate diphenyl methylthio acetyl chloride, amidation to obtain the intermediate diphenyl methylthio acetamide, and final sulfur-oxidation to obtain ultimate product Modafinil. The synthesis process of the present invention has facile material, mild reaction condition, relatively simple preparation and purification, and high product yield and quality, and is suitable for industrial production.
Owner:浙江华纳药业有限公司
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com